Skip to main content
OpenTrials
Completed

NCT Number: NCT01181609

A Study of Avastin (Bevacizumab) Combined With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum

This study will assess the efficacy and safety of intravenous Avastin in combination with chemotherapy regimens as second-line treatment of metastatic cancer of the colon or rectum. The anticipated time of study treatment is until disease progression.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Colorectal Cancer Colonic Diseases Colorectal Neoplasms Digestive System Diseases Digestive System Neoplasms Gastrointestinal Diseases Gastrointestinal Neoplasms Intestinal Diseases Intestinal Neoplasms Neoplasms Neoplasms by Site Rectal Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Angers, France

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients with metastatic colon or rectal cancer, progressing or relapsing after first-line treatment;
  • Women of childbearing potential must use adequate contraception up to at least 6 months after the last dose of bevacizumab.

Exclusion criteria

  • Patients with metastatic colon or rectal cancer scheduled for a first-line systemic treatment;
  • Untreated brain metastases, spinal cord compression or primary brain tumours;
  • Pregnant or lactating women;
  • Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to study start;
  • Treatment with any investigational drug, or participation in another investigational study, within 30 days prior to enrollment.

Treatment and study plan

bevacizumab [Avastin]

Drug

5 mg/kg every 2 weeks or 7.5 mg/kg every 3 weeks according to the chemotherapy regimen

Primary outcomes

  1. Percentage of Participants Achieving Overall Disease Control (ODC)

    Time frame: Baseline, after every other cycle to disease progression or death (Maximum of 52.5 months follow-up)

    ODC was defined as the percentage of participants with measurable disease at baseline who on assessment achieved complete response (CR), partial response (PR), or stable disease (SD) according to Response Evaluation Criteria in Solid Tumors (RECIST). CR defined as disappearance of all target lesions, non-target lesions, and normalization of tumor marker level. PR was defined as greater than or equal to (≥) 30 percent (%) decrease under baseline of the sum of the longest diameter (LD) of all target lesions. SD defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease, taking as reference the smallest sum LD since start of treatment. CR and PR were confirmed no less than 4 weeks after the criteria for response were met.

Secondary outcomes

  1. Percentage of Participants Achieving a Best Overall Response of CR or PR

    Time frame: Baseline, every cycle to progression or death (Maximum of 52.5 months follow-up)

    Percentage of participants achieving CR or PR as defined by RECIST criteria. CR defined as disappearance of all target lesions, non-target lesions, and normalization of tumor marker level. PR was defined as ≥30% decrease under baseline of the sum of the LD of all target lesions. CR and PR were confirmed no less than 4 weeks after the criteria for response were met.

  2. Progression-Free Survival (PFS) - Percentage of Participants With an Event

    Time frame: Baseline, every cycle to progression or death (Maximum of 52.5 months follow-up)

    PFS was defined as the time from start of study treatment to investigator assessed disease progression, or death due to any cause, whichever comes first. Progression was based on tumor assessments made by the investigators according to RECIST.

  3. PFS - Time to Event

    Time frame: Baseline, every cycle to progression or death (Maximum of 52.5 months follow-up)

    PFS was defined as the time from start of study treatment to investigator assessed disease progression, or death due to any cause, whichever comes first. Progression was based on tumor assessments made by the investigators according to RECIST. Median PFS was estimed using the Kaplan-Meier method.

  4. Duration of Response

    Time frame: Baseline, every cycle until progression or death (Maximum of 52.5 months follow-up)

    Duration of response was defined as the time in months from the day of CR or PR was first noted to the day of progression of disease, death or last follow-up. Median duraiton of response is estimated sing the Kaplan-Meier method.

  5. Duration of Overall Disease Control

    Time frame: Baseline, every cycle until progression or death. (Maximum of 52.5 months follow-up)

    ODC duration was defined as the time in months, from when measurement criteria were first met for CR, PR, or SD (whichever status was recorded first) until the first date when progressive disease or the death from any cause was documented. Data were censored for participants who were lost to follow-up, discontinued prematurely without progression/death, or who reached the end of study without progression. Median ODC was estimated using the Kaplan-Meier method.

  6. Overall Survival (OS) - Percentage of Participants With an Event

    Time frame: Baseline, every cycle to progression or death (Maximum of 52.5 months follow-up)

    Overall survival was defined as the time from start of study treatment to death from any cause.

  7. OS - Time to Event

    Time frame: Baseline, every cycle to progression or death. (Maximum of 52.5 months follow-up)

    OS was defined as the time from start of study treatment to death from any cause. Median OS was estimated using the Kaplan-Meier method.

Sponsors and collaborators

Lead sponsor

Hoffmann-La Roche

Industry

Registry information

Official study title

An Open-label Study of Avastin in Combination With Chemotherapy Regimens as Second-line Treatment in Patients With Metastatic Colon or Rectal Cancer

Important dates

Study start
2005
Primary completion
2010
Study completion
2010
First posted
Aug 13, 2010
Registry last updated
Jul 28, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.